▼Read More
https://tech-matome.com/archives/54832
▼Read More
https://tech-matome.com/archives/54832
(Perfil)
(Perfil)
The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
https://www.byteseu.com/2490194/
Chinese and Indian companies won a string of biosimilar (copycat biologic drug) approvals in the U.S. and European Union …
https://www.byteseu.com/2490194/
Chinese and Indian companies won a string of biosimilar (copycat biologic drug) approvals in the U.S. and European Union …
🇺🇸 #$MRK Merck raised 2026 non-GAAP EPS outlook to $2.77 to $2.82 from $2.66 to $2.76, including a new $0.12 charge, and its sales floor to $66.8bn.
Q3 sales $18.1bn, +5%, helped by about $0.55bn of purchase timing. #Keytruda $8.6bn, +6%; Qlex $830m.
midgardfinance.com/companies/MRK/
🇺🇸 #$MRK Merck raised 2026 non-GAAP EPS outlook to $2.77 to $2.82 from $2.66 to $2.76, including a new $0.12 charge, and its sales floor to $66.8bn.
Q3 sales $18.1bn, +5%, helped by about $0.55bn of purchase timing. #Keytruda $8.6bn, +6%; Qlex $830m.
midgardfinance.com/companies/MRK/
Formycon: „Wir gehören zur Spitzengruppe“ - Interview www.4investors.de/nachrichten/...
Formycon: „Wir gehören zur Spitzengruppe“ - Interview www.4investors.de/nachrichten/...
Zydus Lifesciences and Formycon AG jointly announced that the USFDA has accepted for review the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), which the companies believe is the first publicly...
🧵 continued ↓
Zydus Lifesciences and Formycon AG jointly announced that the USFDA has accepted for review the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), which the companies believe is the first publicly...
🧵 continued ↓
#medsky #healthcare #hospice #healthpolicy #homehealth
#medsky #healthcare #hospice #healthpolicy #homehealth
For Keytruda, #biosimilar manufacturers will be free to produce & market versions of the intravenous formulation when the initial patents expire.
More ⬇
For Keytruda, #biosimilar manufacturers will be free to produce & market versions of the intravenous formulation when the initial patents expire.
More ⬇